Pieris Pharmaceuticals Inc.
13F holders, Q2 2024 (June 30)20holders
1famous investor
$9.86avg. 13F price*
At the end of Q2 2024, 20 institutions reported holding Pieris Pharmaceuticals Inc. in their 13F filings. The largest holders were BVF Inc. ($2.5M), Lynx1 Capital Management LP ($427K) and BlackRock Inc. ($127K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Pieris Pharmaceuticals Inc.
- CUSIP
- 720795202
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024
No earlier quarter to compare with.
Ownership 20 holders
| BVF Inc. | 0.07% | No change | 257,626 | $2.5M |
| Lynx1 Capital Management LP | 0.15% | Reduce -60.4% | 43,499 | $427K |
| BlackRock Inc. | 0.00% | No change | 12,975 | $127K |
| Renaissance Technologies | 0.00% | Reduce -35.8% | 11,471 | $113K |
| Vanguard Group Inc. | 0.00% | No change | 11,342 | $111K |
| Acadian Asset Management LLC | 0.00% | Reduce -10.0% | 10,827 | $106K |
| Geode Capital Management, LLC | 0.00% | Add +10.0% | 10,623 | $105K |
| UBS Group AG | 0.00% | Add +165.6% | 1,726 | $17K |
| Citigroup Inc. | 0.00% | No change | 1,108 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -37.5% | 334 | $3K |
| Group One Trading LLC | 0.00% | Add +0.5% | 323 | $3K |
| US Bancorp \de | 0.00% | Add +23.0% | 158 | $2K |
| Morgan Stanley | 0.00% | Reduce -4.3% | 82 | $805 |
| Barclays PLC | 0.00% | Add +0.7% | 63 | $618 |
| Wells Fargo & Company | 0.00% | Reduce -13.9% | 60 | $589 |
| JPMorgan Chase & Co. | 0.00% | Add +8.6% | 27 | $267 |
| Bank of America Corp. | 0.00% | Reduce -83.1% | 13 | $128 |
| Osaic Holdings, Inc. | 0.00% | Add +8.5% | 7 | $69 |
| Allworth Financial LP | 0.00% | Add +14.3% | 5 | $37 |
| Royal Bank of Canada | 0.00% | Add +17.6% | 4 | $0 |
"% of holder's portfolio" is PIERIS PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Pieris Pharmaceuticals Inc. the manager owns.